Fintel · Oct 22, 2026
SN
NYSE · SNN
Smith & Nephew plc
Healthcare · Medical - Devices
$29.70
Down-$0.71 (-2.33%)
Updated Oct 31, 2026, 5:34 PM
SID Score
5.2/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 14.34B
- P/E ratio
- 29.03
- Dividend yield
- 2.57%
- 52-week range
- $26.12 – $37.09
- Volume
- 1.73M
- Avg. volume
- 605.67K
Price performance · SNN
SNN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SNN closed at $29.70 after 21 trading sessions, up 12.41% for the selected period.
- Last close
- $29.70
- Period change
- +12.41%
- Period low
- $26.42
- Period high
- $30.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $29.87 | $30.13 | $29.675 | $29.70 | 1.73M |
| Oct 29, 2026 | $30.14 | $30.41 | $30.04 | $30.41 | 1.57M |
| Oct 28, 2026 | $29.91 | $30.30 | $29.90 | $30.12 | 1.05M |
| Oct 27, 2026 | $30.33 | $30.33 | $29.96 | $30.10 | 852.91K |
| Oct 26, 2026 | $30.54 | $30.64 | $30.33 | $30.47 | 1.3M |
| Oct 23, 2026 | $31.18 | $31.21 | $30.83 | $30.83 | 1.34M |
| Oct 22, 2026 | $29.61 | $30.89 | $29.60 | $30.88 | 1.64M |
| Oct 21, 2026 | $29.00 | $29.46 | $28.99 | $29.23 | 819.09K |
| Oct 20, 2026 | $29.14 | $29.445 | $29.09 | $29.32 | 807.25K |
| Oct 19, 2026 | $28.78 | $28.95 | $28.69 | $28.84 | 635.03K |
| Oct 16, 2026 | $29.21 | $29.38 | $28.94 | $29.06 | 1.31M |
| Oct 15, 2026 | $28.71 | $29.095 | $28.48 | $29.09 | 1.94M |
| Oct 14, 2026 | $27.92 | $27.955 | $27.6099 | $27.88 | 860.35K |
| Oct 13, 2026 | $27.86 | $27.965 | $27.565 | $27.86 | 971.84K |
| Oct 12, 2026 | $27.39 | $27.67 | $27.23 | $27.67 | 1.01M |
| Oct 9, 2026 | $27.20 | $27.35 | $26.99 | $27.24 | 982.9K |
| Oct 8, 2026 | $26.56 | $26.965 | $26.46 | $26.96 | 1.05M |
| Oct 7, 2026 | $27.05 | $27.14 | $26.84 | $26.89 | 1.05M |
| Oct 6, 2026 | $27.10 | $27.14 | $26.68 | $26.87 | 1.6M |
| Oct 5, 2026 | $26.47 | $27.00 | $26.45 | $26.92 | 1.87M |
| Oct 2, 2026 | $26.34 | $26.495 | $26.12 | $26.42 | 1.23M |
Latest SNN news
The latest Smart Investors Daily articles mentioning SNN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SNN research
Overview
Company profile and research snapshot.
Company profile
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | Shore Capital | Buy | — |
| Jun 29, 2026 | RBC Capital Markets | Sector Perform | — |
| Jun 11, 2026 | Deutsche | Hold | — |
| Jun 10, 2026 | RBC Capital Markets | Sector Perform | — |
| May 21, 2026 | Jefferies | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
3 British Undervalued Stocks Trading Up To 38% Below Fair Value
UK inflation has moved to 3.5% in the run up to the first Healey Budget, and talk of further interest rate hikes is back on the table. That kind of backdrop often puts pressure on weaker businesses while leaving cash rich, conservatively financed companies overlooked. This article highlights three London listed stocks that combine solid balance sheets with healthy cash flows and currently trade at prices that our value work suggests are discounted. The three stocks covered below are only a...
ChartMill · Oct 20, 2026
Smith & Nephew (NYSE:SNN) Looks Like a Decent Value Stock
Smith & Nephew (SNN) screens as decent value: cheap vs peers, strong profitability, adequate health and growth, with balanced risks and a 2.95% dividend.
Yahoo · Oct 18, 2026
Top 3 British Undervalued Stocks To Watch In October 2026
High UK debt interest costs are back in the headlines after ministers floated bending fiscal rules to keep green spending going. That kind of flexibility can unsettle bond markets and push up funding costs, which tends to reward companies that already throw off solid cash. This article highlights three London listed businesses where current prices sit below estimated fair value based on their future cash flows. The three stocks below are only a small sample of what this cash flow focus picks...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
